Archive for the ‘Medicine 2.0’ Category

The Future of Clinical Laboratory Courier Services: Technical and Economic Solutions for the Medical Courier Business

March 7, 2012

FREE Special Edition White Paper

download your report now!

Download Your FREE Special Report Today!
Simply Complete the Form Below

 

cover-dark-daily-white-paper-courier-servicesIf you consider a million physicians sending patient samples to a quarter million laboratories, and larger hospitals and health systems having multiple laboratories, clinics, and hospitals, as well as from patient service centers (PSCs) to laboratories, it’s easy to understand just how vital the medical courier system is to the healthcare system in general and the clinical laboratory industry specifically.

If you envision the travel of patient specimens as a very complicated web of time and condition-dependent medical samples in constant motion, then the challenges, both technical and economic, become obvious.  Here are some common questions…

How do you track samples?  How are samples handled?  How do you keep costs down?  How do you operate an efficient courier system if, on any given day, you don’t know the number and types of samples that will be transported?

The Dark Report is happy to offer our readers a chance to download our recently published FREE White Paper “The Future of Clinical Laboratory Courier Services: Technical and Economic Solutions for the Medical Courier Business” at absolutely no charge. This report will address these issues above, provide solutions, and include case studies that show how it is currently being handled.

 

download your report now!

Among other topics, this FREE White Paper specifically addresses:

  1. The economics and fees of a medical lab courier service
  2. Case study, Yale Pathology Labs
  3. Courier transparency and visibility… and much more

For more about closing the medical data gap in your lab, please CLICK HERE.

download your report now!

Table of Contents

Introduction — Page 3

  • How do you track samples?
  • How are samples handled?
  • How do you keep costs down?
  • How do you operate an efficient courier system?

Chapter 1: Medical Laboratory Courier Logistics — Page 4

  • Physician Ordering
  • Sample Collection & Labeling
  • Sample Delivery
  • Sample Processing
  • Reporting

Chapter 2: Laboratory Specimen Handling and Tracking — Page 7

  • Medical Security
    • HIPAA
    • CAP
    • OSHA
    • TSA
  • Chain of Custody
  • In Transit Tracking

Chapter 3: The Economics of Medical Laboratory Courier Services — Page 11

  • Flat Fee
  • Charge Per Mile
  • Charge per Pickup

Chapter 4: Courier Visibility/Transparency — Page 13

  • Training
  • Uniforms
  • Route Analysis
  • Volume Analysis
  • Logistic Experts

Chapter 5: Case Studies — Page 18

  • Yale Pathology Labs (Yale University)
  • LMC Pathology Services (Las Vegas, NV)

Conclusion — Page 24

Appendices

A-1 About Walter J. Humphrey and Susan M. Uihleiny — Page 26

A-2 About Medifleet — Page 27

A-3 About DARK Daily — Page 28

A-4 About The Dark Intelligence Group, Inc., and THE DARK REPORT — Page 29

A-5 About the Executive War College on Laboratory and Pathology Management — Page 30

A-6 About Mark Terry — Page 32

 Terms of Use — Page 36

download your report now!

 

AccelPath Collaborating With Scanner Manufacturers

March 7, 2012

GAITHERSBURG, MD and WESTWOOD, MA, Mar 06, 2012 (MARKETWIRE via COMTEX) — AccelPath, LLC ("AccelPath" or the "Company"), a wholly-owned and operating subsidiary of Technest Holdings, Inc., conducts ongoing discussions with several scanner manufacturers.

AccelPath is in discussions with several slide scanner manufacturers to provide their equipment to clinics and hospitals. Scanner deployments will allow the Company to further digitize all aspects of pathology services, allowing advancement of its strategy of providing efficient, timely, fully automated, digital pathology services using existing electronic information technologies. AccelPath will also utilize these relationships to further advance clinics and hospitals with worksite planning, technical services (including software interfaces and scanner operations), network engineering, professional pathology services and post implementation support.

"We are excited about the significant progress being made toward implementation of digital pathology. This would complete a fully digital loop between treating physician and trained pathologist," said Shekhar Wadekar, the Company's Chief Executive Officer. "We are gaining customer acceptance of our workflow solution and this will increase customer awareness and confidence in the Company's product offerings."

About AccelPath AccelPath provides technology solutions that play a key role in delivering information required for diagnosis of diseases and other pathologic conditions with and through its associated institutional pathologists. The medical institutions, with whom the Company partners, prepare comprehensive diagnostic reports of a patient's condition and consult with referring physicians to help determine the most appropriate treatment. Such diagnostic reports enable the early detection of disease, allowing referring physicians to make informed and timely treatment decisions that improve their patients' health in a cost-effective manner. The Company seeks out referring physicians and histology laboratories in need of high-quality pathology interpretations and manages HIPAA-compliant digital case delivery and reporting while developing comprehensive solutions for managing medical information.

AccelPath is currently focused on the $14 billion anatomic pathology market in the US. The Company's business model builds upon the expertise of experienced pathologists to provide seamless, reliable and comprehensive pathology and special test offerings to referring physicians using conventional and digital technologies. The Company establishes longstanding relationships with the referring physicians as a result of focused delivery of its partner's diagnostic services, personalized responses and frequent consultations, and its proprietary flexible information technology, or IT, solutions that are customizable to the referring physicians or laboratories as well as the pathologists' needs. Such diagnostic reports often enable the early detection of disease, allowing referring physicians to make informed and timely treatment decisions that improve their patients' health in a cost-effective manner. AccelPath's IT and communications platform enables it to efficiently and securely deliver diagnostic reports to referring physicians. In addition, AccelPath's IT platform enables close tracking and monitoring of medical statistics.

Technest focuses on the design, research, development and integration of three-dimensional imaging devices and systems primarily in the healthcare industries. The Company also develops solutions and intelligent surveillance devices and systems, as well as three-dimensional facial recognition systems for security and law enforcement agencies. Historically, the Company's largest customers have been the National Institutes of Health and the Department of Defense. The Company's solutions leverage several core proprietary technology platforms, including 3D imaging technologies.

Additional Company information may be found on the Internet at:

www.accelpath.com

Forward-Looking Statements This press release contains certain "forward-looking statements" relating to the business of the Company, which can be identified by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "intend," "estimate," "believe," "project," "continue," "plan," "forecast," or other similar words, or the negative thereof, unless the context requires otherwise. These statements include, but are not limited to, statements about the Company's current discussions with scanner manufacturers, the Company's expected future performance and the acceptance of the Company's product offerings. The results anticipated by any or all of these forward-looking statements may not occur. In addition, these statements reflect management's current views with respect to future events and are subject to numerous risks, uncertainties and other factors that could cause actual results to differ materially from those set forth in or implied by these forward-looking statements. Factors that could affect those results include, but are not limited to, our ability to conclude our discussions with these manufacturers on favorable terms, the acceptance of our solutions in the marketplace, the efforts of our sales force, general economic conditions, and those described in the Company's reports on Forms 8-K, 10-Q and 10-K and proxy statements and information statements, which have been or will be filed by the Company with the Securities and Exchange Commission (the "SEC"), including without limitation under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed on October 13, 2011. Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company's ability to control or predict. The Company undertakes no obligation and expressly disclaim any obligation, to revise or publicly update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Marketwatch

iPad helps saves man’s life

March 4, 2012

Think the iPad is just for e-mail, eMagazines and Angry Birds? Even before the anticipated release of iPad3 very shortly with a higher resolution monitor, the iPad has been credited with helping to save a man's life. 

Still think it couldn't work for digital pathology?  Read an eSlide, make an eDifference? Get the right diagnosis for the right patient at the right time?

Still think Pathology 2.0 doesn't have a place along side Medicine 2.0?

Keep reading…

The world-renowned Mayo Clinic in Rochester, Minnesota has been issuing iPads to physicians for a while, and now one of the Apple tablets is credited with helping to save the life of a man who suffered an arterial blockage at the facility.

As reported in the Post-Bulletin newspaper, 48-year-old Andy McMonigle was working out with his cycling club at the clinic's Dan Abraham Healthy Living Center when he began to feel intense pressure in his arm. McMonigle has a history of heart trouble, so he immediately went to the locker room and asked a man for help. That man was Mayo Clinic internal medicine resident Dr. Daniel Leuders, who stayed by the side of McMonigle and yelled loudly for assistance.

03-01 andy mcmonigle sj

Two other Mayo residents (brothers Daniel and Christopher DeSimone) were literally just around the corner, so when they arrived Leuders reached into his backpack and pulled out his iPad. Within seconds, Leuders was connected to the Mayo's electronic medical record system, where he was able to pull up McMonigle's medical history.

 

The history showed that McMonigle had a heart stent installed after a previous heart attack four years ago, which made the physicians suspect that he was suffering from a blockage in the stent. When an ambulance crew arrived, Leuders and the other physicians held the iPad record of McMonigle's previous EKG alongside the strip chart that was being printed in real time. What they saw further confirmed their suspicions about the blockage.

The physicians made a choice based on the EKG records that probably saved McMonigle's life. Rather than wait upwards of three hours to run a blood test to verify the clotting, the doctors rushed McMonigle to the cardiac catheterization lab where a team (alerted by activating an emergency code) was waiting. They removed the clot from his artery, which was about 90 percent blocked.

Within three days, McMonigle was released from the hospital and after four more days, he was working out again at the Healthy Living Center.


 

Closing The Medical Data Gap: Using IT To Close The Gap Between Health Information Systems And External Documents

March 2, 2012

FREE Special Edition White Paper

download your report now!

Download Your FREE Special Report Today!
Simply Complete the Form Below

Closing The Medical Data Gap: Using IT To Close The Gap Between Health Information Systems And External Documents

Healthcare creates a wealth of data. Every patient encounter, even a routine checkup, generates a significant volume of information ranging from personal identification data such as Social Security number, age, and address, to clinician notes and impressions, patient data like blood pressure, temperature, pulse, as well as complexlaboratory information.

The trend is toward digital medical information, automated data entry, and the use of Electronic Health Records (EHR), Electronic Medical Records (EMR), Laboratory Information Systems (LIS) and Health Information Exchanges (HIE), among many other health IT tools. Healthcare reform and various government-led stimulus packages have further pushed the digital revolution onto healthcare. Nonetheless, there is a significant gap between reality and full adoption of digital medical information. A great deal of information is still produced on paper. Integrating it into an EHR for digital archiving, search, retrieval and analysis is a difficult, expensive and time-consuming task.

The Dark Report is happy to offer our readers a chance to download our recently published FREE White Paper “Closing The Medical Data Gap: Using IT To Close The Gap Between Health Information Systems And External Documents” at absolutely no charge. This free download will provide readers with a detailed explanation of how to improve Health Information Systems and IT in the laboratory environment.

 

download your report now!

Among other topics, this FREE White Paper specifically addresses:

  1. Structured Data Versus Unstructured Data
  2. Different Data Approaches
  3. Specific Data Gap Solutions in Detail…and More

For more about closing the medical data gap in your lab, please CLICK HERE.

download your report now!

Table of Contents

Introduction — Page 3

Chapter 1. Structured Data Versus Unstructured Data — Page 5

Chapter 2. The Push For Digital Medical Data — Page 7

Chapter 3. The Laboratory Environment — Page 8

Chapter 4. Data Approaches — Page 10

Chapter 5. Data Gap Solutions – Extract Systems — Page 14

 Chapter 6. Data Gap Filled — Page 16

 References — Page 18

Appendices

A-1 About Mark Terry — Page 20

A-2 About Extract Systems — Page 21

A-3 About DARK Daily — Page 22

A-4 About The Dark Intelligence Group, Inc., and THE DARK REPORT — Page 23

A-5 About the Executive War College on Laboratory and Pathology Management — Page 24

A-6 About David Rasmussen — Page 26

 Terms of Use — Page 28


download your report now!

Virtual Microscopy – Real Regulations

February 29, 2012

 

Nice read by Dr. Stacey Mills over at Pathology Network (Pn Blog). A recognized expert in surgical pathology and director of such at the University of Virginia, he writes, "It seems somewhat surprising, at least to me, that a technique based on standard light microscopy, with microscopes being essentially unregulated, Class I devices, should be given the "highest risk" class III rating." Vendors will have to speak to this at upcoming USCAP meeting.  I hope the word "surprise" is not in their vocabulary given statements made on this topic back at the FDA panel meeting in 2009 and inviting the FDA back to Pathology Visions for guidance on the subject.

The lead article in the January 2012 issue of CAP Today addresses the pending FDA regulation of whole slide imagers (WSI's). The FDA has concluded dthat these devices are "Class III" medical devices, and as such are subject to considerable federal regulation (compared to Class I and II devices).  Depending on your perspective, this is either a good thing for patient safety or the death knell for rapid development, certification and deployment of these devices in the United States, with many companies looking elsewhere for testing and validation).
 
By way of quick review, Class I devices are lowest risk and require no pre-market notification.  Your light microscope is, believe it or not, classified as a Class I device.  Class II devices are considered "moderate risk" and are usually based on modifications of prior approved devices or techniques.  Class III devices are considered "highest risk" and such devices require premarket FDA approval, quality controls, etc. Automated cytology screeners, for example, are Class III devices. The FDA has said that WSI's belong in this category as well.
 
It seems somewhat surprising, at least to me, that a technique based on standard light microscopy, with microscopes being essentially unregulated, Class I devices, should be given the "highest risk" Class III rating.  Although the rationale for that decision may be difficult to fathom, it has, in fact, been made and is highly unlikely to be reversed.
The fact that the FDA has even been reviewing WSI's and has decided to regulate them as "highest risk" Class III devices, may come as a surprise to most end-user pathologists since the topic of regulation is understandably not a major one at trade shows where vendors try to sell these devices.  It certainly isn't a topic the vendors themselves are likely to bring up, at least until now.
 
Although the FDA has been less than specific in discussing their thinking, they have indicated that they have concerns about image quality when compared to standard light microscopy, and the effect of navigating on a computer screen v. moving a slide on a microscope.  It is even unclear whether WSI's might be approved for a certain TYPE of specimen or group of diagnoses and not for other types or groups.  Might it be approved for small core biopsies and not for big tissue blocks?  Might it not be approved for hematologic malignancies, where the diagnosis often requires viewing large areas at relatively high magnification, something that is more difficult with a WSI?  At this point, no one knows.  Clinical trials comparing the accuracy of WSI's v. traditional microscopy will be difficult to construct and time consuming to perform, but will likely provide the data to answer these questions.
 
Given the FDA's pace of action in regard to other issues, it's now expected that it may take up to five years for the first devices to be approved in the United States, with Aperio likely to be among the first.  Some companies will most likely concentrate their efforts in Europe where the approval process (and subsequent sales) are likely to be much more rapid.
 
There are many unanswered questions at this early juncture, but it does seem clear that buying and using a WSI for clinical (not research) diagnosis would not be a prudent move at this point in time.  If you are currently using a WSI for primary clinical diagnosis, you had better have "state of the art" (whatever that is!) validation policies in effect, and even then your CLIA or CAP inspection is likely to be problematic.   Even when these instruments gain approval, their use for diagnosis at a distance will fall under the highly diverse state laws regarding telemedicine.  A topic I covered in one of my early blogs, "Down the Telepathology Rabbit Hole."

Published: 2/27/2012

Read more…

 

 

Mills

Stacey E. Mills, MD, a graduate of University of Virginia (UVA) and the UVA Medical Center, has authored nearly 230 articles, 20+ books, atlases and monographs—including the renowned Sternberg's Diagnostic Surgical Pathology. He has been a practicing Professor and Staff Pathologist at UVA for 30+ years and is Director of Surgical Pathology and Cytopathology. His clinical specialty is general surgical pathology with emphasis on neoplasms and neoplasm-like lesions. Dr. Mills is also Editor-in-Chief of The American Journal of Surgical Pathology.

 

Web applications and cloud hosting bring new affordable options to Digital Pathology

February 28, 2012

Web applications and cloud hosting bring new affordable options to Digital Pathology

Tissue Imaging is ready to go digital. In the last decade technology advances in hardware, computing, networking as well as declining storage prices have made storing and handling Whole Slide Images technically viable. The advantages of digital imaging are apparent and market size for pathology is significant, so a flock of companies from pioneers like Aperio and BioImagene, to established players like Leica, Zeiss, Olympus, Phillips and GE got busy working on innovative digital solutions for pathologists.

Today they have solutions that work well, but with the technical problem solved, the economic problem remains for typical pathology lab.  The Digital Pathology package usually includes a slide scanner, an image server and  software for handling and viewing digital slides, and will cost upwards of $150K for a typical installation. This price tag may be attainable for a large hospital chain with capital budgets and IT staff, but 80% of US pathology labs are small business employing staff of 10 people or less.  They are service providers that charge “by the drink” and have no capital budgets or IT support.  They cannot justify large IT investments or technical support staff.

For those who spent their careers in IT, this looks all too familiar: remember those old enterprise IT systems? If you wanted to have company email, share calendar and access your files remotely on the same server, you would have to spend hundreds of thousands of dollars on servers, software and IT support.  That is until cloud and web applications came along.  Now any small business can get big business IT for affordable monthly rate as long as it is connected to the internet, and every large tech company from Cisco to Microsoft is working hard to package their technology offerings for small businesses.

Serving the small business market economically is the inevitable next step and a challenge for Digital Pathology vendors. Number of industry innovators like Mikroscan, DigiPath, Objective Imaging, ViewsIQ and others are pushing technology envelope trying to bring the cost of equipment within the affordability range for a typical lab. They manage to bring hardware price under $30K. Yet, there is another challenge to overcome: small businesses have “0-0-0” expectation from technology. That means zero installation effort, zero learning curve and zero support. They need technology that “just works” and expect vendors to deliver it. The logical solution: cloud hosting and web applications. If done right, cloud software and web applications can bring the same benefits to pathology labs as they did to other businesses in other areas.

Image_gallery

Houston-based software company, Smart Imaging Technologies aspires to bring cloud computing and web applications for whole slide imaging to Digital Pathology with software called Simagis Live. The company experience offers insights for those who are considering whole slide imaging in the cloud:

Upload. Once you move imaging server from the local network, uploading digital slides becomes a critical issue.  Traditional remote upload methods like FTP or WebDav do not work well for large image files; they drop data packets and take forever to complete the job. Smart Imaging had to develop special Turbo Upload Utility that can take Whole Slide Image or folder with image tiles and move it to remote server at blazing speed of 1.5 GB/ minute on high-speed internet connection, all with just 3 mouse clicks, right from the web browser. 

Access and Sharing. Small businesses do not conform to unified corporate IT policies. They use variety of computers, operating systems and browsers. So, the web image browser should “just work” across all computers, operating systems and browsers too, period. And don’t forget tablets! “Just works” means nothing to download, install or update before you can view digital slide online, be it on Windows, Mac, iPad, or Android tablet. Sharing and collaboration process in general should be both easy and secure. Users can invite collaborators and share digital slides in a few clicks, but also they should be able to separate shared and private images and revoke access at any time.

Integration. This issue is absolutely critical to success. In order to meet “0-0-0” expectation, the software should work seamlessly with the imaging hardware, making connections and handling images behind the scenes.  Simagis Live software, for example, includes nifty integration feature called “MicroPlug”.  It adds additional menu option “Save and Share” to imaging device software. When user clicks it, the digital slide is saved to disk and uploaded to user workspace on cloud server at the same time, automatically behind the scenes. The Company does not mind if an imaging device manufacturer puts custom branding on top of the software, in fact it encourages OEM and custom branding solutions as they deliver the most cohesive experience to the end user.  

Business Model and PricingSoftware technology vendors have to structure their offeringsso that they are paid the same way that their clients are paid and make money when their clients make money. They have to give customers no-obligation trials and free-tier service to try the new technology. Cloud software and web applications can provide that flexibility. In the case of Simagis Live, anybody can sign up for free service and get 2GB of space on public application server. If they like the experience, they can get additional space, rent private cloud server or install software on-site.  Clients can pay for only what they, by month or by image, with no upfront capital investments, long-term commitments, installation or IT costs.

In the coming years tissue imaging will follow the path of other imaging modalities like X-ray, CT and MRI and turn digital.  Web applications hold a lot of promise for Digital Pathology and Tissue Diagnostics.  Cloud software can make digital solutions affordable and universally accessible and we should see a lot of interesting developments in this area in the near future. 

 ROI

Visiopharm Introduces APPsolute Digital Pathology

February 24, 2012

Cloud computing and models using software as a service are increasingly being used on a "per use" or "per case" basis as similar stories related to cloud computing on this blog have appeared. 

It is getting increasingly harder to talk about software with folks without being asked "Is there an app for that?"  The reasons for this are many – lower cost, ease of use, minimal development needed and ready "out of the box" as well as potentially increased portability on small screen mobile devices, tablets and pads.

Now comes word from Visiopharm their entrance into this space with some patent pending technology to facilitate image analysis with free trial, low cost and lowered upfront costs to implement software locally and maintain.

Icon-140-appcenterIcon-140-appcenter 

For the clinical market, "per-click" models have been attempted on the hardware side in the past.  These models may create a

disincentive to use versus a larger initial investment as folks get charged per case, per slide or per view.  For software such as image analysis, however, this model makes a lot of sense.  Use what you need when you need it that is proven and reliable from a library of tried and true algorithms.  

If you need to customize, you can create on demand with lower cost, risk and demonstration of performance as you need it.

Dr. Grunkin's quote below pretty much sums this up by lowering many barriers to entry.

For more information on this new offering leverage hosted computing and per analysis offering, check out Visiopharm's webinar mentioned at the end of the below press release and their booth at the upcoming USCAP meeting.

APPsolute Digital Pathology offers a novel approach to Quantitative Digital Pathology. Powered by CloudAnalysis and the APPCenter; currently featuring over 25 ready-to-use Analysis Protocol Packages (APPs).

APPsolute Digital Pathology is a novel approach to Quantitative Digital Pathology (QDP); costs are reduced, the learning curve is minimized, and the common risks of adoption are eliminated. The Visiopharm APPCenter provides access to a library of solutions that are ready-to-run and can be used with minimum training. Analysis Protocol Packages (APPs) can be tested free of charge before investing, productivity is achieved immediately, the upfront costs are low, and solutions can be scaled to fit customer needs.

A Pay-As-You-Go Solution: Low upfront costs

CloudAnalysis and APPs provide a low cost, easy to budget solution for customers who need access to sophisticated image analysis capabilities for a specific amount of time. Whether it is a week, a month, or longer you only pay for analysis when you need it.

Michael Grunkin, PhD, President of Visiopharm, stated "Currently, the cost structure of commercially available deployed Quantitative Digital Pathology solutions prevents the majority of researchers from benefitting from this increasingly important technology. This has to change. With our CloudAnalysis the upfront investment can be reduced to a fraction of any existing deployed solution. With CloudAnalysis there is always access to the most recent software version, studies can be run from anywhere, and technical deployment issues are eliminated."

The patent pending APPCenter provides customers with easy access to an extensive library of ready-to-run APPs. Each APP includes detailed descriptions, references to scientific literature, illustrated examples, webinars, and more. There is no need to become an expert in image analysis; APPs are created and validated in collaboration between experts in the field and Visiopharm’s application scientists and programmers.

Customers try an APP free of charge, before investing, to make sure that 1) the APP is working according to specifications, 2) the APP provides useful results, and 3) the APP can be understood and operated.

APPs are purchased for a low fixed cost, are yours to keep, and will work with both Visiopharm’s DeployedAnalysis and CloudAnalysis solutions. Custom APPs can be developed upon request, at a fixed known cost, and are also risk free with a complimentary trial.

"In a research project involving 300 patients, we worked with Visiopharm’s Image Analysis APPs developed for five different biomarkers. We could work seamlessly on the cloud, we were productive within an hour or two of training, and were able to complete and review the analysis of 5 x 300 tissue specimens in less than a week. The results we achieved were at least as good as manual scoring, and in several cases significantly better. The speed, convenience, and cost structure offered by CloudAnalysis and Image APPs makes Quantitative Digital Pathology an efficient, affordable, and attractive research tool", says Dr. Lars D. Andersen, Associate Professor, Group Leader, Center for Molecular Clinical Cancer Research, Department of Molecular Medicine (MOMA).

Built on leading technology

CloudAnalysis provides instant access from work, home, or from anywhere to the complete suite of Visiopharm software solutions; including advanced image analysis and stereology. Simply log in to your secure account and start to analyze your slides locally or in the cloud.

CloudAnalysis is built upon proven Whole Slide image analysis technology. Johan Doré, CTO at Visiopharm says, "Our solutions have been stress-tested over the last 10 years in the most demanding environments when it comes to capabilities, automation, and throughput. The feedback we consistently get from the world’s most experienced and sophisticated Digital Pathology users is, that we provide solutions with a lower learning curve, lower cost of ownership, by far the lowest computational costs, while providing high quality results."

Visit Visiopharm’s new website at http://www.visiopharm.com to learn more about APPsolute Digital Pathology and [register] for an introductory webinar on March 14, 2012 at 11 AM EST titled “Squaring the Circle of Quantitative Digital Pathology: instant implementation, while increasing productivity and achieving a return on investment."  In this webinar Visiopharm will demonstrate this new generation of software for Quantitative Digital Pathology with a flexible, affordable method of delivery in the Cloud.

About Visiopharm

Over the past 10 years, Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, clinical researchers, and academic researchers all over the world. Visiopharm has more than 300 deployed systems worldwide and a large network of distribution and support partners, and is featured in over 400 scientific publications.

Source: Visiopharm


Corista inks deal with MGH and Partners Healthcare

February 23, 2012


Corista to provide platform for Massachusetts General Hospital's Pathology Network

The Massachusetts General Hospital Pathology Service has chosen Corista's Digital Image Management Platform (DP3) to support its goal of providing clinical review of pathology cases with a digital platform. This new capability will allow MGH clinical experts to extend their reach to remote patients and their physicians for second opinions in real time.

"Recent technological advances have enabled immediate and widespread access to highly specific pathology expertise, speeding up both diagnosis and the start of treatment," said David Wilbur, MD, Director , Clinical Imaging -Pathology Services at MGH and Professor of Pathology at Harvard Medical School. "The key is having an image-centric platform that provides access together with the tools needed to respond and interact with multiple systems in the community."

 

Corista

Corista’s CEO, Elizabth Wingard said , "We’re pleased to be working with MGH and Partners Healthcare to extend the reach of the hospital’s expertise in pathology to physicians and patients in communities near and far. The Corista platform provides an intuitive case management dashboard that manages workflow and patient cases with digital images, and which can be integrated with existing hospital information systems," Wingard said. "In accessing specialists online and getting an immediate response, remote patients and hospitals can improve patient care with expertise that would have been delayed by days using couriers and FedEx. Eliminating the delay improves the patient’s care by enabling providers to initiate the appropriate treatment plan immediately."

 

Corista provides Pathologists with a single point of access to read and manipulate patient images with an extensive toolset for analysis, collaboration, diagnosis and report generation. With Corista's platform, MGH will be able to improve the process and quality of pathology medicine while extending real time clinical support for remote patients. 

About Corista

Since 2005, Corista has been developing its image-based processing software and proprietary browser-based software platform.  The patent-pending platform, DP3, provides a comprehensive solution for pathology practices that includes: a universal viewer that reads images from any whole slide imaging platform; secure local and remote image viewing and navigation, image management, on-demand colleague consultation, annotation, measurement  diagnoses; notifications to physicians of new cases or consults to be reviewed, and a centralized Physician Dashboard integrating in-house and remote patient cases into a single view for physicians. DP3 can integrate with existing hospital information systems, is hardware agnostic and supports a complete range of physician devices including high resolution monitors, tablets and touchscreens. 

 

Study

Full size image

Source: Corista

 

Back to the Future: Video Telepathology

February 17, 2012

 

Btfstill

The following non-bolded text that appears are excerpts from an upcoming book chapter to be published shortly.  

Preparation for the book chapter pre-dated now a couple of looks at Remote Meeting Technologies "Anytime, anywhere, anything!" technology that makes the claim "No specimen is too big or too small for iMedHD™ and our Be There Anywhere™ telemedicine solutions. Even gross specimens, autopsy, gram stains, and transbronchial needle aspirations can be safely and securely broadcasted to another location on site, across town, across the country, or across the world! The compact iMedHD™ is the ideal solution for cost effective, real-time High Definition sharing of images over the internet. iMedHD™ is compatible, flexible, and will enable collaboration on multiple applications throughout the pathology department and laboratories including Consultations, Gross, Intraoperative, Tumor Boards and FNA & TBNA".

Reviewing slides and gross images in high-definition got me to thinking about the first experiences with telepathology and video microsocopy: 

Telepathology is the practice of pathology at a distance, obtaining macroscopic and/or microscopic images for transmission along telecommunication links with remote interpretations (telediagnosis), second opinions or consultations (teleconsultation), and/or for educational purposes. “Tele” is a Greek prefix that means “distant.” Various terms that have been used in conjunction with telepathology include digital microscopy, remote robotic microscopy, teleconferencing, teleconsultation, telemicroscopy, video microscopy, virtual microscopy, and whole slide imaging. In the practice of telepathology, the original material (tissue, glass histology slide, etc) is separated by distance from the remote consultant (telepathologist). Remotely viewed digital or analog images, or digital whole slides, get interpreted by the telepathologist on a computer monitor (or even a cell phone screen) rather than through conventional light microscope eyepieces. Today, virtually ubiquitous access to the Internet, or to other broadband telecommunications linkages, on many continents, facilitates nearly global image sharing. As a result, telepathology has been used to aid a growing number of laboratories in providing pathology services over great distances, and has even been used by others to increase the efficiency of services between hospitals less than a mile apart.

With increasing sub-specialization in pathology, the use of telepathology to access subspecialists (e.g. neuropathologists, dermatopathologists) is also on the upswing and is proving to be cost-effective in at least certain settings. The practice of telepathology is not only limited to rendering diagnoses, but can also play important roles in quality assurance (e.g. re-review of cases), teaching, and research. When telepathology is widely viewed as an acceptable ancillary technique, it will likely become a common tool integrated into mainstream diagnostic pathology.

Pathology and oncology, just as the rest of medicine is becoming increasingly subspecialized, particularly in community settings.

Dr. Ron Weinstein introduced the term “telepathology” into the English language in 1986. In the late 1960’s, he was a pathology resident at the Massachusetts General Hospital (MGH) when the first real-time “television microscopy” service was established between the Logan Airport Medical Station and the MGH in Boston, Massachusetts.  He observed early demonstrations of the technology and became aware of the limitations of video microscopy when microscopic field selection was performed by a nurse or a medical technologist at the Logan Airport clinic.  The vast majority of cases did not require an on-site pathologist, since most of the clinical cases involved remotely viewing blood smears and urines. This Logan Airport television microscopy system was not used for surgical pathology cases.

Nearly two decades later, Weinstein differentiated video microscope technologies, including “television microscopy” and “video microscopy,” from “telepathology” for good reason. He proposed that the “practice of telepathology” would require that a “telepathologist”, who would be rendering a telediagnosis, should be able to control remotely all relevant light microscope functions (e.g., using a motorized, robotically controlled light microscope) in order to use telepathology for surgical pathology cases.  Ideally, selection of the diagnostic microscopic fields would be made by the remote telepathologist, using some type of dynamic telepathology system that would accentuate inclusive microscope field selection at a range of viewing magnifications.

Now, thanks to Remote Meeting Technologies, true high-definition, brilliant color, high-definition video is possible for pathology for both gross and microscopic imaging.  True 1920 x 1080p resolution shared very quickly over standard networks. 

No scanning, uploading or downloading required.  Point-to-point connectivity with browser-based viewer for ease of use and easy to control.  

Perfect technology for remote consultations, frozen sections, cytology evaluations, gross review at a distance, etc…

This is not to suggest you can avoid purchasing a whole slide scanner as well for the complete imaging platform but I think there is going to be a renewed trend towards live non-robotic imaging between pathologists, although the lack of stitching here to create an image is a nice point from the regulatory perspective, like, not subject to it…

True 1080p microscopy to share with colleagues, cinicians and patients with brilliant monitors to show every detail.  

If you are looking for real-time imaging with high-def video, check out Remote Meeting Technologies.  Combined with very low-cost high-speed networks you can share diagnostic quality images quickly and easily.

So now, more than 25 years after the first telepathology demonstration in this country, forget about low resolution of 300 lines over expensive satellite networks and the like,  and see pathology in high-definition.

It is fun to look back and to the future.  What will the next generation of this latest technology look like? Perhaps teleport to the bedside without the Delorean?

Back-tofuture-delorean-660

 

Telepathology became a newsworthy item in 1986 with the first public demonstration of a satellite-linked color-video dynamic telepathology system. Fort William Beaumont Army Medical Center in El Paso, Texas, and Washington DC were linked for the demonstration. The dynamic-robotic telepathology system used for the demonstration was designed and fabricated by Weinstein’s group at Rush Medical College, in Chicago in partnership with Corabi International Telemetrics, Inc., a Rush University spin-off company located in a nearby Illinois state-owned biotechnology incubator facility, in west Chicago. The Corabi patented technology combined the use of digital and analog video imaging for the first time. Digital imaging was used to produce a small tissue map, which was captured and displayed, in a low resolution digital image format, on a navigation system monitor. This auxiliary imaging system was used by the remote telepathologist to manage the robotic motorized microscope’s functions. The telepathologist always knew exactly where the motorized microscope’s objective was positioned in relation to the actual tissue section mounted on the glass slide.  Use of the auxiliary navigation system also helped ensure that each entire slide was imaged by the telepathologist-system operator in the course of a telepathology diagnostic session. The magnitude and expense of the effort to create this external navigation system reflected Weinstein’s high level of concern that the Achilles heel of telepathology could turn out to be inadequate histopathology image sampling. His concern proved to be well founded as “limiting sampling” static image telepathology (i.e., sampling of one or only a few fields), was practiced in early commercial static image telepathology systems. Such systems are no longer marketed in the United States. Real-time analog imaging was used for viewing the images of the slide during the diagnostic session in the Texas-Washington, D.C. robotic telepathology demonstration. 

The story appeared on page 7 of the Metro section in the Washington Post:

Nextbestthingtobeingthere

 

For the actual Texas-to-Washington, D.C. proof-of-concept demonstration of robotic-dynamic telepathology, a histopathology slide of a hematoxylin and eosin (H&E)-stained breast frozen section, was processed into a low resolution whole slide digital image, using a low resolution camera mounted on a light box. After the navigation system digital slide was produced, the same breast tissue frozen section slide was remounted on the stage of an Olympus remotely controllable motorized photo-microscope. A stream of analog video images, viewed on a larger monitor, was used for rendering the diagnosis. The analog video images were transmitted, via satellite, to the boardroom of COMSAT Corporation, in Washington, D.C. A telepathologist, Dr. Alexander Miller, seated at a Corabi prototype workstation, was able to control all of the functions of the motorized microscope in Texas, including stage movements, magnification, focus and illumination, while viewing the real-time images, at 525 lines of resolution, with a video monitor refresh rate of 30 frames per second. The navigation system, positioned near the large video monitor, displayed tissue mapping parameters.  Superimposed over the low resolution digital image of the breast frozen section, displayed on the navigation system screen, was a small box-shaped icon indicating the location and size of the field-of-view (FOV) of the glass slide being actively displayed on the main video monitor. Velocity of the stage movements, displayed as lateral movements of the small FOV box, showed the exact relationship of the light microscope’s objective lens to the underlying tissue section. The location of FOV was automatically updated as Dr. Miller, in Washington, D.C., robotically repositioned the glass slide on the microscope’s motorized stage in Texas. Changes in magnification initiated by Dr. Miller, by the press of a button, appeared natural. Focus was easily controlled during scanning of the slide, and readily re-established with each change in magnification. Two-way audio communication was maintained between the laboratory in Texas and the Washington, D.C. COMSTAT boardroom throughout the dynamic telepathology diagnostic session. Technicians and doctors in Texas were in constant communication with Dr. Miller.

 

 

 

Specialists On Call Renews Joint Commission Accreditation

February 15, 2012

Courtesy of Business Wire:

Specialists On Call, Inc. (SOC), the nation's leading provider of clinical telemedicine, announced today that it has completed its 2012 Joint Commission review and maintained their accreditation. SOC provides hospitals nationwide with immediate 24/7 access to board certified specialty physicians via telemedicine and delivers over 1,500 emergency consultations each month.

"This is a very big deal for Specialists On Call," commented Dr. Joe Peterson, CEO of SOC. "We've always distinguished ourselves by the clinical quality we offer hospitals and renewing our Joint Commission accreditation validates that commitment to excellence. Completing this Joint Commission Survey with no findings is rare and furthers our leadership position within the industry."

Specialists On Call was the first free-standing and commercial telemedicine service to earn Joint Commission accreditation and this latest evaluation was SOC's third formal review. To date, SOC has helped more than 40,000 patients and their family members with time sensitive clinical consultations via telemedicine.

SOC's growth plan for 2012 includes multiple new telemedicine service lines that address the nation's growing specialty physician shortage. Last year Specialists On Call launched an emergency telepsychiatry service for hospitals that are hard pressed to provide 24/7/365 psychiatric on-call coverage in their emergency room. Thus far, the telepsychiatry service has produced six times the consult volume that SOC's long-established teleneurology service generated during its first year.

About Specialists On Call

Specialists On Call, Inc. (SOC), is a Joint Commission-accredited organization that is changing emergency medicine. As the leading provider of emergency telemedicine consultations, SOC gives hospitals vital 24/7/365 access to more than 50 board certified, fellowship trained academic specialists, each with a minimum of 10 years experience. With operations on both coasts, SOC provides more than 1,500 emergency consultations per month for hospitals nationwide and hospital systems such as Vanguard Health Systems, HCA, Inc. and Tenet Healthcare Corporation.

For more information please visit www.specialistsoncall.com

Source: Specialists On Call, Inc.

 


Follow

Get every new post delivered to your Inbox.